Also agree with your sentiments john12, however the short / med term value in this stock is clearly FDA approval (which I think is likely) and not commercialisation of ilumen. In the longer term (say 12-24m) post FDA there will be some upside to revenue growth but SP is all about FDA!!
Ann: FDA Strategy and Regulatory Update, page-251
-
- There are more pages in this discussion • 442 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
